Skip to main content

09-30-2020 | EASD 2020 | Conference coverage | Article

DAPA-CKD: Does confirmed renoprotection make the case for first-line SGLT2 inhibition?

Luigi Gnudi reflects on what the findings of DAPA-CKD mean for diabetologists, nephrologists, and treatment guidelines (6:10).

Read the transcript

Related topics

Virtual EASD Annual Meeting 2020 coverage

Catch-up with news stories and expert commentary.

Image Credits